for investors

Investors

corporate profile
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).
stock
snapshot
Additional stock info »
09.24.2020 | 3:28 AM EDT
Copyright West LLC. Minimum 15 minutes delayed.
Press Releases
Sep 11, 2020
Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Aug 25, 2020
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
Aug 25, 2020
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome
View all news »
Events & Presentations
Sep 17, 2020 2:00 PM EDT
Ovid Therapeutics Inc at 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Aug 25, 2020 8:00 AM EDT
ELEKTRA Positive Topline Results Conference Call
Aug 6, 2020 12:00 PM EDT
Ovid Therapeutics Inc at William Blair Biotech Focus Conference 2020
View all events and presentations »
Latest Corporate Presentation Get the Ovid primer— download our latest corporate presentation for investors.
Explore the Ovid Pipeline The Ovid pipeline includes several candidates that would potentially be the first to make a meaningful impact in the lives of individuals with rare neurological conditions. View our pipeline »
Get Investor Updates Have the latest on the BOLD happenings at Ovid, from clinical trial endpoint and data announcements to corporate news, sent right to your inbox. Sign up now »
latest updates